Market Place
Sourcing Support
Ascletis Completes Phase 3 Enrollment for ASC40 in Acne Treatment
12 Nov 2024 //
PR NEWSWIRE
Ascletis Announces Phase I Results for ASC47 in Obesity
07 Nov 2024 //
PR NEWSWIRE
Ascletis Enters Obesity Drug Space With Phase I Trials Of GLP-1R Agonist ASC30
17 Sep 2024 //
PR NEWSWIRE
Ascletis Announces Strategic Decisions on FXR agonist ASC42
03 Apr 2024 //
PR NEWSWIRE
Ascletis Pharma scraps liver disease program; Another reverse merger
03 Apr 2024 //
ENDPTS
Ascletis Announces Presentation of PII Final Results of FASN Inhibitor ASC40
10 Mar 2024 //
PR NEWSWIRE
Ascletis’ Gannex reports positive interim PhII NASH data
02 Jan 2024 //
ENDPTS
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40
05 Dec 2023 //
PR NEWSWIRE
Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023
12 Nov 2023 //
PR NEWSWIRE
Ascletis Announces Positive Data from Phase IIb Expansion Cohort of ASC22
28 Sep 2023 //
PR NEWSWIRE
Ascletis Announces Completion of Enrollment of Patients in PIII Trial of ASC40
25 Sep 2023 //
PR NEWSWIRE
Clinical Results of ASC22 in Combination with Chidamide Presented at 12th IAS
24 Jul 2023 //
PR NEWSWIRE
Ascletis Announces China NMPA Approval of Conducting a Ph IIa Trial for ASC10
08 May 2023 //
PR NEWSWIRE
Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor
02 May 2023 //
PR NEWSWIRE
Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index
27 Feb 2023 //
PR NEWSWIRE
Ascletis Presented Positive Phase I Data for Double Prodrug ASC10 at CROI
20 Feb 2023 //
PR NEWSWIRE
Presentation at APASL Demonstrates ASC22 Can Achieve Cure of Chronic Hepatitis B
16 Feb 2023 //
PR NEWSWIRE
Coronavirus (COVID-19) Current Therapy Global Market Report 2023
14 Feb 2023 //
PR NEWSWIRE
Ascletis Announces U.S. FDA Approval of Conducting PIIa Trial for ASC10
31 Jan 2023 //
PR NEWSWIRE
Ascletis doses subjects in first cohort of Covid-19 oral therapy trial
16 Jan 2023 //
CLINICAL TRIALS ARENA
Ascletis Announces Entering into a Agreement of Ritonavir Tablets with Simcere
16 Jan 2023 //
PR NEWSWIRE
NAFLD clinical trial activity catching up in Chin, lacks domestic participation
27 Dec 2022 //
INDIANPHARMAPOST
Ascletis` NASH Drug ASC41(THR?) Phase II Enrollment is Progressing as Planned
20 Dec 2022 //
PR NEWSWIRE
Ascletis Announces Notice of Issuance of the U.S. Patent for ASC10
19 Dec 2022 //
PRNEWSWIRE
Ascletis reports positive data from Phase I Covid-19 prodrug trial
13 Dec 2022 //
CLINICALTRIALSARENA
Ascletis Announces Positive PhI Clinical Results of Oral RdRp Inhibitor ASC10
12 Dec 2022 //
PRNEWSWIRE
China NMPA grants IND clearance for trial of Ascletis’ Covid-19 drug
08 Dec 2022 //
CLINICALTRIALSARENA
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11
07 Dec 2022 //
PRNEWSWIRE
Ascletis Announces Completion of 180 Patient Enrollment for Ph II Clinical Trial
30 Nov 2022 //
PRNEWSWIRE
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19
23 Nov 2022 //
PRNEWSWIRE
Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61
16 Nov 2022 //
PRNEWSWIRE
Ascletis Announces IND Approval of Viral Polymerase Inhibitor ASC10
15 Nov 2022 //
PRNEWSWIRE
Ascletis Announces Poster Presentation of Phase I of ASC43F for NASH
06 Nov 2022 //
PRNEWSWIRE
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19
01 Nov 2022 //
PRNEWSWIRE
Ascletis Announces U.S. IND Filing of Antiviral ASC10 for Monkeypox Indication
26 Oct 2022 //
PRNEWSWIRE
Ascletis doses healthy subjects in Phase I trial of oral Covid-19 tablets
10 Oct 2022 //
CLINICALTRIALSARENA
Ascletis Announces Dosing of Subjects of First 3 Cohorts in PhI Trial of ASC10
09 Oct 2022 //
PRNEWSWIRE
Ascletis Announces Dosing of First Patient in PII Trial of THR? Agonist ASC41
04 Oct 2022 //
PRNEWSWIRE
Ascletis Announces Dosing of the First Patient in the Phase IIb of ASC22
27 Sep 2022 //
PRNEWSWIRE
Ascletis announces completion of patient enrolment in study of PD-L1
16 Sep 2022 //
PHARMABIZ
China NMPA grants IND clearance for Ascletis’ Covid-19 therapy
22 Aug 2022 //
PHARMACEUTICAL-TECHNOLOGY
Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10
21 Aug 2022 //
PRNEWSWIRE
Gannex doses first participant in primary biliary cholangitis DDI study
16 Aug 2022 //
CLINICALTRIALSARENA
Ascletis Begins Dosing in U.S. PI Trial of ASC61 for Advanced Solid Tumors
07 Aug 2022 //
PRNEWSWIRE
Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10
03 Aug 2022 //
PRNEWSWIRE
NMPA Accepts Ascletis` IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19
03 Aug 2022 //
PRNEWSWIRE
Ascletis Files IND for Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
05 Jul 2022 //
PRNEWSWIRE
SPHCC Completed 1st Patient Dosing in Study of PD-L1 Antibody ASC22 + Chidamide
04 Jul 2022 //
ASIAONE
Ascletis Begins Dosing in PII Trial of ASC22 for HIV-1 Infection
28 Jun 2022 //
PRNEWSWIRE
Ascletis` Subcutaneous PD-L1 Antibody ASC22 for Chronic Hepatitis B
26 Jun 2022 //
PRNEWSWIRE
Ascletis Announces Oral Presentation on Updates from PIIb Trial of ASC22
15 Jun 2022 //
PRNEWSWIRE
Ascletis Appoints Mr. John P. Gargiulo as Chief Business Officer
12 Jun 2022 //
PRNEWSWIRE
Ascletis (1672.HK) Included in MSCI China Small Cap Index
16 May 2022 //
PRNEWSWIRE
Ascletis Announces U.S. IND Approval of ASC22 in HIV
11 May 2022 //
ASIAONE
Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential in COVID-19
19 Apr 2022 //
PRNEWSWIRE
Ascletis Cooperates with China Meheco in Distribution of Its Ritonavir Tablets
13 Apr 2022 //
PRNEWSWIRE
Ascletis Announces China IND Approval of ASC60 for Advanced Solid Tumors
06 Apr 2022 //
PRNEWSWIRE
Ascletis Announces Completion of First Sale of Its Ritonavir Tablets
04 Apr 2022 //
PRNEWSWIRE
Ascletis Submits MAA for Ritonavir in Hong Kong
03 Apr 2022 //
PRNEWSWIRE
Ascletis Announces Latest Results of PC Studies of ASC61 & ASC60 for AACR
27 Mar 2022 //
PRNEWSWIRE
